Composite TREs for Compact AAV Vectors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Gene therapy vectors, such as AAV, face challenges in achieving optimal expression and stability due to size limitations, with existing promoters like HCR-hAAT and FRE72 having limitations in terms of expression efficiency and transduction rates, especially when used with transgenes of varying sizes.
Innovation Solution
Development of a panel of transcription regulatory elements (TREs) comprising hAAT and AMBP sequence elements, along with additional promoter and enhancer elements like ApoE-HCR1, ALDOB, CRM6, and F2, which can be tailored to different sizes to enhance expression levels beyond those achieved by HCR-hAAT and FRE72.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If very small promoters are used in AAV vectors to deliver transgenes close in size to the viral genome, then the vector size remains optimal for manufacturability and transduction, but expression efficiency may be insufficient
Solution Approach 1:
The patent combines multiple promoter elements (hAAT promoter, AMBP enhancer, and additional liver-specific enhancer elements) into a single integrated transcriptional control unit. This merging creates a composite promoter structure that achieves high expression efficiency while maintaining a compact size suitable for AAV vectors, resolving the contradiction between expression efficiency and promoter size.
Solution Approach 2:
The invention creates a composite promoter structure by integrating different functional DNA elements (promoter core, enhancer regions, and liver-specific regulatory sequences) into a unified transcriptional control element. This composite structure leverages the synergistic effects of multiple elements to achieve superior expression efficiency within the size constraints of AAV vectors.
2Adaptability or versatility
If stuffer sequences are added to increase expression cassette size, then the vector can accommodate larger transgenes, but production efficiency, stability, and transduction rates may be reduced
Solution Approach 1:
The patent removes the need for stuffer sequences by designing highly efficient compact promoters that maximize transgene expression within the available AAV vector capacity. This extraction of unnecessary inert DNA elements improves viral vector stability and transduction rates while maintaining the ability to accommodate therapeutic transgenes.
Solution Approach 2:
The invention optimizes the transcriptional control element parameters by selecting and combining specific promoter and enhancer elements that achieve maximum expression efficiency in a minimal size footprint. This parameter optimization allows the expression cassette to accommodate larger transgenes without requiring stuffer sequences, thereby maintaining viral vector stability.
3Productivity
If larger promoters are used to enhance expression levels, then transgene expression efficiency improves, but the vector size moves away from the optimal 4.7 kbp AAV genome size
Solution Approach 1:
The patent segments the transcriptional control function into distinct modular elements (promoter core, enhancer regions, and liver-specific regulatory sequences) that can be independently optimized and combined. This segmentation allows for the creation of a compact yet highly efficient promoter structure that enhances transgene expression without excessively increasing the overall expression cassette size.
Solution Approach 2:
The invention creates a dynamic transcriptional control system by integrating multiple regulatory elements that can respond to cellular signals and transcription factors. This dynamic structure achieves high expression efficiency through coordinated regulation rather than relying on simple size increases, allowing optimal expression levels within the AAV vector size constraints.
Data Source
AI summary
The present invention relates to transcription regulatory elements (TREs) based on the combination of a hAAT sequence element and an AMBP sequence element and which promote greater expression than HCR-hAAT. The invention further relates to compositions comprising the AAV vectors, as well as methods of gene therapy based on the use of such vectors and compositions.